Profile lipid and obesity in patients with Tms to treatment with antipsychotis

Psychiatric patients tend to have severe metabolic alterations of multifactorial causes, lifestyle, diet, drug use and psychopharmacological treatment, especially antipsychotic drugs which act as risk factors for cardiovascular disease, strokes, infections and complications of diseases basal negativ...

Full description

Saved in:

Bibliographic Details
Published in:	European psychiatry Vol. 41; no. S1; pp. S684 - S685
Main Authors:	Suaréz, A. González, García, L. Lago, Huerta, A. Alonso, León, S. Ocio, Simon, M. Gómez, González, M.J. Hernández, Rodriguez, O. Walid Muquebil Ali Al Shaban, Suarez, M.P. Estebanez, Salas, I. Barreda, Fernandez, J. Lopéz, Ortiz, D. Frias, Ojea, E. Torio
Format:	Journal Article
Language:	English
Published:	Elsevier Masson SAS 01-04-2017
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Psychiatric patients tend to have severe metabolic alterations of multifactorial causes, lifestyle, diet, drug use and psychopharmacological treatment, especially antipsychotic drugs which act as risk factors for cardiovascular disease, strokes, infections and complications of diseases basal negatively influencing its evolution and prognosis. Rating the profile lipid and the prevalence of obesity in patients registered as disorder mental severe in treatment with antipsychotics. A descriptive study was performed taking as variables to take into account levels of cholesterol, triglycerides, weight and size. Of the 28 patients included in the study 7 refused to perform the corresponding measurements. Of the 21 remaining, 3 showed values higher than 150mg/dl triglycerides and cholesterol figures higher than 200mg/dl. Other 3 patients presented hypercholesterolemia without alteration of triglycerides and 2 hypertriglyceridemia without elevation of the cholesterol. Concerning the IMC, found that 7 patients presented overweight (BMI>25 and<30) and 5 patients obesity (BMI>30). Of the 8 patients with lipid disorders, 2 had prescribed treatment with risperidone (oral or injectable) more quetiapine, 2 oral risperidone as monotherapy, risperidone1 more amisulpride, 1 quetiapine more aripiprazole, quetiapine 1 in monotherapyand 1 injection invega more oxcarbamacepina. We found lipid alterations in a 38.1% of patients and a BMI greater than 25 in a 57.14% of 21 patients who agreed to the study. The most prescribed antipsychoticamong these patients were risperidone (5 patients) followed closely by quetiapine (4 patients).
ISSN:	0924-9338 1778-3585
DOI:	10.1016/j.eurpsy.2017.01.1191